Somewhat less than three years ago, I wrote two articles on Behemoth stocks which I define as stocks with over $100 Billion of market cap. Today I want to revisit those stocks, and those that have joined them.

Blockbuster status, an unofficial gold medal awarded to therapies racking up sales of $1 billion or more per year, is the holy grail for drug developers. Here's a look at three recently approved drugs already on the way to becoming blockbusters.

Sleigh bells ring, are you listenin'? In the markets, the Dow is glistenin'...and so are the other major averages.

The best scoring ADRs have outpaced the EFA by an average and median 422 bps and 535 bps over the following year, respectively, with 0% turnover. The top performers include KUBTY, BAYRY, and VIP.

The great potential of a drug or remedy that may make it a significant seller and revenue driver for years to come is one thing. But the partners and interested parties early on and along the way suggests a depth that a long term stakeholder should pay attention to.